Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Pfizer (NY: PFE)
38.33 USD  -0.21 (-0.54%)
Official Closing Price  /  Updated: 7:55 PM EST, Dec 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 15,824,100
Open 38.51
Bid (Size) 38.29 (4)
Ask (Size) 38.52 (1)
Prev. Close 38.54
Today's Range 38.07 - 38.68
52wk Range 33.97 - 44.56
Shares Outstanding 5,849,571,048
Dividend Yield 3.55%
Performance
YTD
-11.38%
-11.38%
1 Month
+4.87%
+4.87%
3 Month
+4.07%
+4.07%
6 Month
-10.61%
-10.61%
1 Year
-12.49%
-12.49%
Top News
More News
Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of... Read More
from Business Wire News Releases
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of... Read More
from Business Wire News Releases
More News
Read More
Barron's Picks And Pans: Charles Schwab, Disney, Sprint, Netflix And More
category Barron's , AMTD , S , and 14 more.
from Benzinga
UPDATE 1-Pfizer's rare disease drug gets EMA's positive recommendation
category companyNews
from Reuters: Company News
Pfizer's rare disease treatment wins EMA's positive recommendation
category companyNews
from Reuters: Company News
ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
from Business Wire News Releases
UPDATE 1-GSK's ViiV seeks marketing licence for baby-friendly HIV pill
category companyNews
from Reuters: Company News
IWD, DIS, INTC, PFE: ETF Outflow Alert
category ETFs
from ETF Channel
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
category BMY , PFE , Market News , and 1 more.
from Motley Fool
3 Biotech Stocks That Can Double Your Money in 2020
category PFE , PTLA , Market News , and 4 more.
from Motley Fool
Why This Pharmaceutical Stock Broke Out Bullishly In Early Action
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.